Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2010

View Archived Issues

Ad28-based adenovirus vector is strongly immunogenic

Daiichi Sankyo claims new Mdm2-p53 interaction inhibitors

German scientists disclose new inhibitors of tau aggregation

Italian researchers describe new antimicrobial agents

New tyrosine-protein kinase inhibitors claimed by sanofi-aventis

New alpha-mannosidase inhibitors identified by Emory University

Mission Pharmacal launches Uribel capsules for symptoms of urinary tract conditions in U.S.

Acrux issues update on female health products

QRxPharma reports encouraging phase II proof-of-concept data on MoxDuo IV

New models predict activity/selectivity of cannabinoid receptor agonists/antagonists

Clomipramine reduces GFAP levels in Alexander's disease model / News in Context

Pfizer describes MR antagonist for diabetic nephropathy

AM-643 is a candidate for topical treatment of skin disorders

Elan and Transition Therapeutics report phase II data on ELND-005 in Alzheimer's disease

FDA grants orphan drug status to CYT-387 for myelofibrosis

Fibrocell Science submits phase II/III Azficel-T trial report to FDA

ILLUMINATE trial supports 24-week telaprevir-based therapy in HCV infection

FDA grants priority review to rifaximin sNDA for non-constipation-predominant IBS

Scancell and Cancer Research Technology sign antibody license agreement

Teva Pharmaceutical acquires ratiopharm

Lentigen receives NIH grant to develop melanoma immunotherapy

Genmab presents phase II ofatumumab data in diffuse large B-cell lymphoma

Shire divests ADHD therapeutic Daytrana to Noven Pharma

NsGene and Biogen Idec sign new agreement for artemin

Advanced Life Sciences and FDA reach SPA agreement for phase III Restanza trial in pneumonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...